Norifumi Harimoto

Dr. Norifumi Harimoto

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NHNorifumi Harimoto
Norifumi Harimoto
TYTomoharu Yoshizumi
Tomoharu Yoshizumi
SIShoichi Inokuchi
Shoichi Inokuchi
SIShinji Itoh
Shinji Itoh
EAEisuke Adachi
Eisuke Adachi
YMYoshihiko Maehara
Yoshihiko Maehara

1 February 2020 in HPB
Verified
Journal Article
Closed access
KAKenichiro Araki
Kenichiro Araki
NHNorifumi Harimoto
Norifumi Harimoto
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
TITakamichi Igarashi
Takamichi Igarashi
KSKen Shirabe
Ken Shirabe

1 December 2015 in Journal of Surgical Research
Verified
Journal Article
Closed access
NHNorifumi Harimoto
Norifumi Harimoto
KSKen Shirabe
Ken Shirabe
TIToru Ikegami
Toru Ikegami
TYTomoharu Yoshizumi
Tomoharu Yoshizumi
TMTakashi Maeda
Takashi Maeda
YMYoshihiko Maehara
Yoshihiko Maehara

4 February 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TYTakahiro Yamanaka
Takahiro Yamanaka
NHNorifumi Harimoto
Norifumi Harimoto
TYTakehiko Yokobori
Takehiko Yokobori
RMRyo Muranushi
Ryo Muranushi
KHKouki Hoshino
Kouki Hoshino
KSKen Shirabe
Ken Shirabe
Background: Intrahepatic cholangiocarcinoma (ICC) is a malignancy that is challenging to treat. Fibroblasts in ICC tissues have been identified as cancer-associated fibroblasts (CAFs) that promote the malignant behaviour of ICC cells. An antifibrotic drug nintedanib has been reported to suppress activated hepatic stellate cells in liver fibrosis. Methods: We investigated whether nintedanib could suppress the cancer-promoting effect of CAFs derived from ICC tissues in vitro and in vivo. Results: CAFs promoted the proliferation and invasion of ICC cells. Nintedanib suppressed activated CAFs expressing α-smooth muscle actin (α-SMA) and inhibited the ICC-promoting effects of CAFs. Nintedanib greatly reduced the levels of cancer-promoting cytokines, such as interleukin (IL)-6 (IL-6) and IL-8, secreted by CAFs. An in vivo study demonstrated that nintedanib reduced xenografted ICC growth and activated CAFs expressing α-SMA, and that combination therapy with nintedanib and gemcitabine against CAFs and ICC cells showed the strongest inhibition of tumour growth compared with the control and single-treatment groups. Conclusions: Nintedanib inhibited the cancer-promoting effect of CAFs via the suppression of CAF activation and secretion of cancer-promoting cytokines. Our findings suggest that therapeutic strategies combining conventional cytotoxic agents with nintedanib targeting CAFs are promising for overcoming refractory ICC with activated CAFs.

25 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
TITakamichi Igarashi
Takamichi Igarashi
NINorihiro Ishii
Norihiro Ishii
SKShunsuke Kawai
Shunsuke Kawai
KSKen Shirabe
Ken Shirabe
Increasing evidence suggests that nutritional indices, including the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI), are predictors of poor prognosis in patients with hepatocellular carcinoma (HCC). Hence, this study aimed to explore the value of the GNRI and PNI in evaluating postoperative prognosis in patients with HCC, particularly regarding its recurrence patterns. We performed a retrospective analysis of 203 patients with HCC who underwent initial hepatic resection. Patients were divided into two groups according to the GNRI (cutoff: 98) and PNI (cutoff: 45). The GNRI and PNI were significantly associated with body composition (body mass index and skeletal muscle mass index), hepatic function (Child-Pugh Score), tumor factors (tumor size and microvascular invasion), and perioperative factors (blood loss and postoperative hospitalization). Patients with a low PNI or low GNRI had significantly worse overall survival (OS) and recurrence-free survival. Patients with early recurrence had lower PNI and GNRI scores than those without early recurrence. Patients with extrahepatic recurrence had lower PNI and GNRI scores than those without extrahepatic recurrence. The PNI and GNRI might be useful in predicting the prognosis and recurrence patterns of patients with HCC after hepatic resection.

26 June 2017 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
NHNorifumi Harimoto
Norifumi Harimoto
TYTomoharu Yoshizumi
Tomoharu Yoshizumi
KSKazuhito Sakata
Kazuhito Sakata
ANAkihisa Nagatsu
Akihisa Nagatsu
TMTakashi Motomura
Takashi Motomura
YMYoshihiko Maehara
Yoshihiko Maehara